These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 2463699

  • 1. Agonistic and antagonistic interactions of anti-interleukin 2 receptor monoclonal antibodies in rat recipients of cardiac allografts.
    Kupiec-Weglinski JW, Tilney NL, Stunkel KG, Grutzmann R, van der Meide PH, Di Stefano R, Diamantstein T.
    Transplantation; 1989 Jan; 47(1):11-6. PubMed ID: 2463699
    [Abstract] [Full Text] [Related]

  • 2. Biodistribution of anti-interleukin 2 receptor monoclonal antibodies correlates with their therapeutic efficacy following transplantation.
    Kupiec-Weglinski JW, Mariani G, Tanaka K, Di Stefano R, Stünkel KG, Diamantstein T, Tilney NL.
    Cell Immunol; 1989 Oct 01; 123(1):148-57. PubMed ID: 2476241
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of action of anti-IL-2R monoclonal antibodies. ART-18 prolongs cardiac allograft survival in rats by elimination of IL-2R+ mononuclear cells.
    Tanaka K, Hancock WW, Osawa H, Stunkel KG, Alberghini TV, Diamantstein T, Tilney NL, Kupiec-Weglinski JW.
    J Immunol; 1989 Nov 01; 143(9):2873-9. PubMed ID: 2530281
    [Abstract] [Full Text] [Related]

  • 4. Evidence that monoclonal antibodies against the 55kD subunit of the rat IL-2 receptor do not inhibit the development of suppressor cells generated in mixed lymphocyte culture.
    Tanaka K, Turka LA, Kupiec-Weglinski JW, Milford EL, Ueda H, Diamantstein T, Carpenter CB, Tilney NL.
    Transplantation; 1990 Jul 01; 50(1):125-31. PubMed ID: 2142344
    [Abstract] [Full Text] [Related]

  • 5. Pretreatment with cyclosporine and anti-interleukin 2 receptor antibody abrogates the anti-idiotype response in rat recipients of cardiac allografts.
    Tanaka K, Tilney NL, Stunkel KG, Hancock WW, Diamantstein T, Kupiec-Weglinski JW.
    Proc Natl Acad Sci U S A; 1990 Oct 01; 87(19):7375-9. PubMed ID: 2217171
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of interleukin 2 receptor-targeted therapy on heart and kidney allografts in rats. Depression of effectiveness of ART-18 monoclonal antibody treatment by uremia.
    Ueda H, Hancock WW, Cheung YC, Tanaka K, Kupiec-Weglinski JW, Tilney NL.
    Transplantation; 1990 Jun 01; 49(6):1124-9. PubMed ID: 2113725
    [Abstract] [Full Text] [Related]

  • 7. Selective immunosuppression with anti-interleukin 2 receptor-targeted therapy: helper and suppressor cell activity in rat recipients of cardiac allografts.
    Kupiec-Weglinski JW, Padberg W, Uhteg LC, Ma L, Lord RH, Araneda D, Strom TB, Diamantstein T, Tilney NL.
    Eur J Immunol; 1987 Mar 01; 17(3):313-9. PubMed ID: 2952511
    [Abstract] [Full Text] [Related]

  • 8. Anti-interleukin 2 receptor monoclonal antibodies spare phenotypically distinct T suppressor cells in vivo and exert synergistic biological effects.
    Di Stefano R, Mouzaki A, Araneda D, Diamantstein T, Tilney NL, Kupiec-Weglinski JW.
    J Exp Med; 1988 Jun 01; 167(6):1981-6. PubMed ID: 2968435
    [Abstract] [Full Text] [Related]

  • 9. The mechanism of synergistic interaction between anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy in rat recipients of organ allografts.
    Ueda H, Hancock WW, Cheung YC, Diamantstein T, Tilney NL, Kupiec-Weglinski JW.
    Transplantation; 1990 Oct 01; 50(4):545-50. PubMed ID: 2219270
    [Abstract] [Full Text] [Related]

  • 10. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.
    Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB.
    Proc Natl Acad Sci U S A; 1986 Apr 01; 83(8):2624-7. PubMed ID: 2939456
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporine and anti-interleukin 2 receptor monoclonal antibody therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms.
    Hancock WW, DiStefano R, Braun P, Schweizer RT, Tilney NL, Kupiec-Weglinski JW.
    Transplantation; 1990 Feb 01; 49(2):416-21. PubMed ID: 2106180
    [Abstract] [Full Text] [Related]

  • 12. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts.
    Binder J, Lehmann M, Graser E, Hancock WW, Watschinger B, Onodera K, Sayegh MH, Volk HD, Kupiec-Weglinski JW.
    Transplantation; 1996 Mar 15; 61(5):804-11. PubMed ID: 8607187
    [Abstract] [Full Text] [Related]

  • 13. Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin.
    Hancock WW, Lord RH, Colby AJ, Diamantstein T, Rickles FR, Dijkstra C, Hogg N, Tilney NL.
    J Immunol; 1987 Jan 01; 138(1):164-70. PubMed ID: 3097143
    [Abstract] [Full Text] [Related]

  • 14. Modulation of accelerated rejection of cardiac allografts in sensitized rats by anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy.
    Kupiec-Weglinski JW, Sablinski T, Hancock WW, Di Stefano R, Mariani G, Mix CT, Tilney NL.
    Transplantation; 1991 Feb 01; 51(2):300-5. PubMed ID: 1825240
    [Abstract] [Full Text] [Related]

  • 15. The role of antibody isotype in IFN-gamma and IL-2 production during anti-CD3-induced T cell proliferation.
    Frenken LA, Koene RA, Tax WJ.
    Transplantation; 1991 Apr 01; 51(4):881-7. PubMed ID: 1826571
    [Abstract] [Full Text] [Related]

  • 16. Evidence that therapeutic strategies targeted at CD4+ cells modulate accelerated rejection of cardiac allografts in sensitized rats by different mechanisms.
    Sablinski T, Sayegh MH, Kut JP, Milford EL, Tilney NL, Kupiec-Weglinski JW.
    Transplantation; 1992 Aug 01; 54(2):292-6. PubMed ID: 1353914
    [Abstract] [Full Text] [Related]

  • 17. Direct evidence of a functional separation of alloreactive T lymphocytes from bystander cells infiltrating rat allografts. Interleukin 2 receptor-positive cells reacting with the monoclonal antibody ART 18 mediating second-set rejection.
    Heidecke CD, Brauer R, Schneider-Eicke J, Schilling T, Wolff S, Diamantstein T.
    Transplantation; 1990 Jul 01; 50(1):101-6. PubMed ID: 2368130
    [Abstract] [Full Text] [Related]

  • 18. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen.
    Arima T, Lehmann M, Flye MW.
    Transplantation; 1997 Jan 27; 63(2):284-92. PubMed ID: 9020332
    [Abstract] [Full Text] [Related]

  • 19. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice.
    Wasowska BA, Qian Z, Cangello DL, Behrens E, Van Tran K, Layton J, Sanfilippo F, Baldwin WM.
    Transplantation; 2001 Mar 27; 71(6):727-36. PubMed ID: 11330533
    [Abstract] [Full Text] [Related]

  • 20. Blocking of interleukin 2 (IL 2) binding to the IL 2 receptor is not required for the in vivo action of anti-IL 2 receptor monoclonal antibody (mAb). I. The production, characterization and in vivo properties of a new mouse anti-rat IL 2 receptor mAb that reacts with an epitope different to the one that binds to IL 2 and the mAb ART-18.
    Mouzaki A, Volk HD, Osawa H, Diamantstein T.
    Eur J Immunol; 1987 Mar 27; 17(3):335-41. PubMed ID: 3106058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.